A single-dose, open-label, randomized, 2-way crossover, clinical pharmacology study of four inhalations of CHF 1535 100/6 NEXT DPI® (fixed combination of beclomethasone dipropionate 100µg plus formoterol fumarate 6 µg) versus the same dose of CHF 1535 100/6 pMDI both administered with charcoal block. - (duplicate) Clinical pharmacology study of CHF1535 NEXT DPI versus CHF1535 pMDI

• Register: EUCTR
• Last refreshed on: 19 March 2012
• Main ID: EUCTR2010-024384-40-GB
• Date of registration: 04/04/2011
• Prospective Registration: Yes
• Primary sponsor: Chiesi Farmaceutici S.p.A.
• Public title: A single-dose, open-label, randomized, 2-way crossover, clinical pharmacology study of four inhalations of CHF 1535 100/6 NEXT DPI® (fixed combination of beclomethasone dipropionate 100µg plus formoterol fumarate 6 µg) versus the same dose of CHF 1535 100/6 pMDI both administered with charcoal block. - (duplicate) Clinical pharmacology study of CHF1535 NEXT DPI versus CHF1535 pMDI
• Scientific title: A single-dose, open-label, randomized, 2-way crossover, clinical pharmacology study of four inhalations of CHF 1535 100/6 NEXT DPI® (fixed combination of beclomethasone dipropionate 100µg plus formoterol fumarate 6 µg) versus the same dose of CHF 1535 100/6 pMDI both administered with charcoal block. - (duplicate) Clinical pharmacology study of CHF1535 NEXT DPI versus CHF1535 pMDI
• Date of first enrolment: 28/04/2011
• Target sample size: 24
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-024384-40
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: no Cross over: yes Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no

Countries of recruitment

United Kingdom

Key inclusion & exclusion criteria

Inclusion criteria:
1. Male and female adults (=18 and = 70 years old). 2. Written informed consent obtained by the patient prior to any study-related procedures. 3. Diagnosis of asthma as defined by the GINA guidelines, update 2009, at least in the 6 months before the screening visit. 4. Asthmatic patients already treated with low or medium daily dose of ICS (e.g. BDP or equivalent = 1000 µg/die) or low dose of ICS/LABA fixed combination (e.g. salmeterol/fluticasone 100/500 µg/die). 5. Patients with a pre-bronchodilator forced expiratory volume in one second (FEV1) = 60% and = 90% of the predicted values. 6. Non or ex-smokers who smoked less than 5 pack-years and stopped smoking for at least 1 year. (Pack/year: number of cigarette smoked per day multiplied by the number of years of smoking/20). 7. Ability to a proper use of pMDI plus spacer and DPI devices. 8. A cooperative attitude to be compliant with study procedures. 9. Body mass index (BMI) =18.5 and = 32 kg/m2
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1. Pregnant or lactating women or all women physiologically capable of becoming pregnant UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with already documented serum FSH levels > 40 mIU/mL or are using one or more of the following acceptable methods of contraception. a)surgical sterilization (e.g. bilateral tubal ligation, hysterectomy) b)hormonal contraception (implantable, patch, oral) c)other forms of effective contraception including placement of an intrauterine device (IUD) or intrauterine system (IUS) or barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal cream/foam/gel/ suppository. 2. Significant seasonal variation in asthma or asthma occurring only during episodic exposure to an allergen or a chemical sensitizer. 3. History of near fatal asthma (e.g. brittle asthma, hospitalization for asthma exacerbation in Intensive Care Unit). 4. Patients with abnormal QTcF at Screening Visit: QTcF > 450 msec for male subjects and QTcF > 470 msec for female subjects. 5. Diagnosis of COPD as defined by the current GOLD guidelines, updates 2009. 6. Hospitalization due to asthma exacerbation within 1 month prior to the screening visit or during the run-in period. 7. Lower respiratory tract infection within one month prior to screening until randomization. 8. History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency. 9. History of drug addiction or excessive use of alcohol (weekly intake in excess of 28 units alcohol; one unit being a glass of beer, wine or a measure of spirits), or excessive consumption of xanthine containing substances (daily intake in excess of 5 cups of coffee, tea, cola, etc) or psychological or other emotional problems likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements; 10. Diagnosis of restrictive lung disease. 11. Patients treated with oral or parenteral corticosteroids in the previous 2 months before the screening visit (3 months for parenteral depot corticosteroids). 12. Intolerance or contra-indication to treatment with B2-agonists and/or inhaled corticosteroids or allergy to any component of the study treatments. 13. Having received an investigational drug within 1 month before the screening visit. 14. Significant medical history of and/or treatments for cardiac, renal, neurological, hepatic, endocrine diseases, or any laboratory abnormality indicative of a significant underlying condition, that may interfere with patient’s safety, compliance, or study evaluations, according to the investigator’s opinion. 15. Any patient with active cancer or a history of cancer with less than 5 years disease free survival time (whether or not there is evidence of local recurrence or metastases). Localized basal cell carcinoma (without metastases) of the skin is acceptable.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Asthma
MedDRA version: 13.1 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders

Intervention(s)

Trade Name: Foster®
Product Name: Fixed combination Beclomethasone Dipropionate (BD) plus Formoterol Fumarate (FF)
Product Code: CHF 1535 100/6 NEXT DPI
Pharmaceutical Form: Inhalation powder
INN or Proposed INN: beclomethasone dipropionate
CAS Number: 5534-09-8
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: Formoterol fumarate
CAS Number: 87833-61-2
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 6-
Pharmaceutical form of the placebo: Pressurised inhalation, solution
Route of administration of the placebo: Inhalation use

Trade Name: Foster®
Product Name: Foster
Product Code: CHF 1535 100/6 pMDI
Pharmaceutical Form: Pressurised inhalation, solution
INN or Proposed INN: beclomethasone dipropionate
CAS Number: 5534-09-8
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 100-
INN or Proposed INN: formoterol fumarate
CAS Number: 87833-61-2
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 6-

Primary Outcome(s)

Secondary Objective: To evaluate the lung bioavailability of BDP. To assess the safety and the tolerability of the study treatments.

Primary end point(s): Pharmacokinetics variable: - Plasma B17MP and formoterol AUC0-t

Main Objective: To compare the lung bioavailability of B17MP (active metabolite of BDP) and formoterol after four inhalations using CHF 1535 100/6 NEXT DPI® and CHF 1535 100/6 pMDI using AeroChamber PlusTM spacer, with activated charcoal to block gastrointestinal absorption.

Secondary ID(s)

CCD-1015-PR-0055